Design Therapeutics develops GeneTAC small molecule drug candidates for inherited diseases caused by repeated gene sequences. It last closed at $9.84 on Nov 17, down 0.81% on the day. The average 12-month price target from 2 analysts is $22.50 (+128.7% from the last close), with a high of $26.00 and a low of $19.00.
Only 2 firms rated DSGN in the past 90 days, not enough for a consensus
Average 12-month target
$22.50
▲ 128.7% upside
Based on 2 analysts who set a price target on DSGN in the past 90 days. The average target is $22.50, with a high of $26.00 and a low of $19.00, compared with the last close of $9.84.
Low $19.00Avg $22.50High $26.00
Blue marker: last close $9.84
Highest target$26.00
Average target$22.50
Lowest target$19.00
Latest rating changes
RBC CapitalMaintained
Nov 5Buy$19
Wells FargoInitiated
Oct 2Buy$26
Date
Firm
Action
Rating
Price target
Nov 5
RBC Capital
Maintained
Buy
$19
Oct 2
Wells Fargo
Initiated
Buy
$26
Loading…
Technical Analysis
DSGN · as of the Nov 17 close · updated after every close
Downtrend
The stock is 6% below its 20 day and 17% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the swing low (Nov 5) at $9.62, and the nearest resistance the Pivot at $9.87.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.5%/day
Key levels
$17.2552 week high+75.3%
$12.79100 day average+30.0%
$12.18200 day average+23.8%
$11.4850 day average+16.7%
$10.98Swing high (Nov 11)+11.6%
$10.4620 day average+6.3%
$10.20Pivot R1+3.7%
$9.87Pivot+0.3%
$9.84Last close
$9.62Swing low (Nov 5)−2.2%
$9.50Pivot S1−3.5%
$7.2452 week low−26.4%
Indicators
RSI (14)
39.56
Weak, oversold below 30
Neutral
MACD
-0.35
Above its signal line
Bullish
Stochastic
26.4
Middle of its range
Neutral
ADX (14)
16.6
No clear trend
Williams %R
-83.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-159.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−4.8%
Change over 10 sessions
Bearish
ATR (14)
$0.64
Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 16.0%/day
Key levels
$17.2552 week high+75.3%
$12.79100 day average+30.0%
$12.18200 day average+23.8%
$11.4850 day average+16.7%
$10.98Swing high (Nov 11)+11.6%
$10.4620 day average+6.3%
$10.20Pivot R1+3.7%
$9.87Pivot+0.3%
$9.84Last close
$9.62Swing low (Nov 5)−2.2%
$9.50Pivot S1−3.5%
$7.2452 week low−26.4%
Indicators
RSI (14)
38.93
Weak, oversold below 30
Neutral
MACD
-0.50
Below its signal line
Bearish
Stochastic
10.4
Near the bottom of its range
Oversold
ADX (14)
25.1
Trending down
Williams %R
-94.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-115.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−32.7%
Change over 10 sessions
Bearish
ATR (14)
$1.57
Typical daily range, 16.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for DSGN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how DSGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow DSGN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DSGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DSGN is in one of them and how their past DSGN trades turned out.
Design Therapeutics is a biopharmaceutical company based in Carlsbad, California, that researches and develops GeneTAC molecules, a type of small molecule. These molecules are designed to target repeated DNA sequences that cause certain inherited diseases, and to adjust how genes are expressed in affected cells. The company's lead candidates are aimed at Friedreich ataxia, Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1. Its candidates are still in development and are intended for patients with these inherited conditions.